Chaffey J T, Hellman S, Rosenthal D S, Moloney W C
Cancer Treat Rep. 1977 Sep;61(6):1149-52.
Seventy-eight patients with advanced lymphocytic lymphoma have been treated by total-body irradiation (TBI) since 1969. Fifty-one of these patients received TBI as their initial and only primary therapy, and of these, 36 had a nodular histology and 15 had a diffuse histology according to the Rappaport classification. Treatment consisted of 15 rads twice weekly to 150 rads total dose. Persistent local tumors were given local boost irradiation. None of these 78 patients experenced significant morbidity; toxicity was confined to thrombocytopenia, and in 40% of the patients treatment was administered over a prolonged course to allow platelet recovery. Of the 51 patients who received TBI as primary treatment, 80% achieved a complete response for a median relapse-free survival of 24 months and an actuarial 5-year survival of 68%. TBI is an effective therapy in advanced lymphocytic lymphoma and produces long remissions without maintenance in many patients. It should be considered a systemic agent, and its use in combination with chemotherapeutic agents deserves further investigation.
自1969年以来，78例晚期淋巴细胞淋巴瘤患者接受了全身照射（TBI）治疗。其中51例患者将TBI作为初始且唯一的主要治疗方法，根据Rappaport分类，这些患者中36例为结节性组织学，15例为弥漫性组织学。治疗方案为每周两次，每次15拉德，总剂量达150拉德。对持续存在的局部肿瘤进行局部强化照射。这78例患者均未出现明显的并发症；毒性仅限于血小板减少，40%的患者接受了延长疗程的治疗以促进血小板恢复。在51例接受TBI作为主要治疗的患者中，80%达到完全缓解，中位无复发生存期为24个月，精算5年生存率为68%。TBI是晚期淋巴细胞淋巴瘤的一种有效治疗方法，许多患者无需维持治疗即可获得长期缓解。应将其视为一种全身性药物，其与化疗药物联合使用值得进一步研究。
